[1]胡 峻,高月求,孙学华,等.肝积颗粒联合肝动脉化疗栓塞术治疗中晚期肝癌近期疗效研究*[J].陕西中医,2020,(9):1237-1240.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.017]
　HU Jun,GAO Yueqiu,SUN Xuehua,et al.Study on the short-term efficacy of Ganji granule combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer[J].,2020,(9):1237-1240.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.017]
点击复制

肝积颗粒联合肝动脉化疗栓塞术治疗中晚期肝癌近期疗效研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年9期
页码:
1237-1240
栏目:
临床研究
出版日期:
2020-09-05

文章信息/Info

Title:
Study on the short-term efficacy of Ganji granule combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer
作者:
胡 峻; 高月求; 孙学华; 乐 凡; 朱晓骏; 周振华; 郑 超; 张景豪; 岑 戎△
上海中医药大学附属曙光医院(上海200021)
Author(s):
HU Jun; GAO Yueqiu;  SUN Xuehua; et al.
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine(Shanghai 200021)
关键词:
中晚期肝癌;  肝动脉化疗栓塞术;  肝积颗粒;  近期疗效;  肝功能;  生活质量
Keywords:
Advanced liver cancer;  Transcatheter arterial chemoembolization;  Ganji granules;  Short-term efficacy;  Liver function;  Quality of life
分类号:
R575
DOI:
DOI:10.3969/j.issn.1000-7369.2020.09.017
文献标志码:
A
摘要:
目的:观察肝积颗粒联合肝动脉化疗栓塞术治疗中晚期肝癌近期疗效。方法:将80 例中晚期肝癌患者按照随机数字表分为治疗组和对照组,每组40 例。对照组予以肝动脉化疗栓塞术治疗,治疗组在肝动脉化疗栓塞术基础上服用肝积颗粒,1剂/d。术后3个月评价近期疗效,观察ALT、AST、GGT、TBIL、ALB等肝功能指标,以及AFP、KPS评分、不良反应发生情况。结果:治疗组有效率为65.0%,对照组分别为42.5%,治疗组近期疗效优于对照组(P<0.05)。组内术后3 个月与治疗前比较,两组ALT、AST、GGT、TBIL水平明显下降,ALB水平明显上升(P<0.05)。术后3个月与对照组比较,治疗组ALT、AST、GGT、TBIL明显下降、ALB水平明显升高,相比较差异均有统计学意义(P<0.05)。组内术后3个月与治疗前相比,两组AFP 水平下降(P<0.05),KPS 水平升高(P<0.05); 组间治疗后比较,AFP、KPS 差异有统计学意义(P<0.05)。治疗组、对照组总体不良反应发生率分别为5.0%、20.0%,比较差异有统计学意义(P<0.05)。结论:肝积颗粒联合肝动脉化疗栓塞术治疗中晚期肝癌,可提高近期疗效,改善患者生存质量,减少不良反应。
Abstract:
Objective:To observe the short-term efficacy of Ganji granules combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer.Methods:80 patients with advanced liver cancer were randomly divided into treatment group and control group,with 40 cases in each group.The control group was treated with transcatheter arterial chemoembolization,and the treatment group received Ganji granules one dose per day,on the basis of transcatheter arterial chemoembolization.The short-term efficacy was evaluated 3 months after operation,and changes in liver function-related laboratory indicators ALT,AST,GGT,TBIL,ALB,AFP,KPS score,and adverse reactions were observed.Results:The effective rate was 65.0% in the treatment group and 42.5% in the control group.The short-term efficacy of the treatment group was better than that of the control group(P<0.05).Compared with before treatment,3 months after operation in the group,the levels of ALT,AST,GGT,TBIL in the treatment group were significantly decreased,and the levels of ALB were significantly increased(P<0.05).Compared with the control group at 3 months after operation,the differences in ALT,AST,GGT,TBIL,and ALB in the treatment group were statistically significant(P<0.05).Compared with before treatment,the AFP level in the two groups decreased(P<0.05)and the KPS level increased(P<0.05)in the 3 months after the operation.There was statistically significant difference in AFP and KPS between groups after treatment(P<0.05).The overall adverse reaction rates of the treatment group and the control group were 5.0% and 20.0%,respectively.There was statistically significant difference in the overall adverse reaction rates between the groups(P<0.05).Conclusion: Ganji granule combined with transcatheter arterial chemoembolization can improve the short-term efficacy,improve the quality of life of patients,and reduce adverse reactions.

参考文献/References:

[1] Shan KZ,Wang YL,Hua HQ,et al.Ginsenoside Rg3 combined with oxaliplatin inhibits the proliferation and promotes apoptosis of hepatocellular carcinoma cells via downregulating PCNA and cyclin D1[J].Biol Pharm Bull,2019,42(6):900-905.
[2] 王俊镔,张 晶,卢冬彦,等.阿帕替尼联合经导管肝动脉灌注化疗栓塞治疗中晚期肝癌临床研究的系统评价[J].安徽医药,2019,23(12):2504-2510.
[3] Carbajo P,Ordonez R,Benet M,et al.Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells[J].British Journal of Cancer,2013,109(1):83-91.
[4] Marco DB,Riccardo S,Claudia L,et al.Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response[J].Cancer Imaging,2019,19(1):1-9.
[5] 段惠龙.不同介入栓塞化疗方案联合射频消融治疗原发性肝癌疗效及对患者免疫功能的影响[J].陕西医学杂志,2018,47(10):1303-1305.
[6] 吴贵成,郭岚岚,杨平生,等.康艾注射液联合异甘草酸镁对原发性肝癌患者肝动脉化疗栓塞术后免疫及肝功能的影响[J].陕西中医,2017,38(11):1497-1498.
[7] 周 芳,白广德.中医药防治原发性中晚期肝癌的近况[J].内蒙古中医药,2014,33(15):6-7.
[8] 张晓轩.健脾理气抑瘤方联合CIK细胞治疗晚期肝细胞癌[D].广州:广州中医药大学,2015.
[9] 李正军.肝动脉化疗栓塞术对原发性肝癌患者的肝功能影响及相关因素分析[D].南京:南京中医药大学,2014.
[10] Hui W,Xi SH,Xin RY,et al.STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4[J].Molecular Cancer,2017,16(1):1-15.
[11] Zheng YJ,Liu YL,Zhao SF,et al.Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma[J].Cancer Management and Research,2018,10(1):6079-6096.
[12] Kudo M,Masatoshi F,Richard S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet,2018,10126(391):1163-1173.
[13] Ghassan K,Abou A,Tim M,et al.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J].The New England Journal of Medicine,2018,379(1):54-63.
[14] Kumar V,Bhatt PC,Rahman M,et al.Umbelliferon-α-d-glucopyranosyl-(2-1)-α-dglucopyranoside ameliorates diethylnitrosamine induced precancerous lesion development in liver via regulation of inflammation,hyperproliferation and antioxidant at pre-clinical stage[J].Biomedicine & Pharmacotherapy,2017,94(3):834-842.
[15] Takeshi H,Hirotaka A,Satoru K.Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma[J].World Journal of Hepatology,2018,10(7):485-495.
[16] Yuan Y,Chen JJ,Jiao DC,et al.Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:a meta-analysis[J].Medicine,2019,98(44):178-183.
[17] 陈 杨,汪名权,宋 文,等.中医药联合TACE对中晚期肝癌患者生存期影响的回顾性队列研究[J].肝胆外科杂志,2018,26(4):292-296.
[18] 乔喜婷,王 昊,杨 林,等.复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究[J].陕西中医,2019,40(8):998-1000.
[19] 黄如意.膈下逐瘀汤加减联合精准肝动脉化疗栓塞术治疗中晚期原发性肝癌临床效果[J].中国现代医生,2019,57(19):36-38,42.
[20] 黄新造,戴列军,庞 洪,等.AFP倍增时间在肝癌患者预后评价中的作用[J].肝脏,2016,21(12):1087-1088.
[21] 刘 敏,张 璐,孙丽华,等.辽宁省肿瘤化疗患者KPS评分情况分析[J].中国肿瘤,2013,22(8):635-637.

相似文献/References:

[1]吉 银,戴 铭,王振常,等.逍遥散合大黄虫丸治疗原发性肝癌经肝动脉化疗栓塞术后气滞血瘀型疗效研究[J].陕西中医,2024,(2):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
　JI Yin,DAI Ming,WANG Zhenchang,et al.Treatment of primary hepatocellular carcinoma qi stagnation and blood stasis type patients after TACE with Xiaoyao San combined with Dahuang Zhechong pill[J].,2024,(9):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]

备注/Memo

备注/Memo:
*上海市卫生健康委员会科研课题(201840101)
更新日期/Last Update: 2020-09-08